Oral deucrictibant for hereditary angioedema attacks
Treatments studied
Part of Genetic & congenital, Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests an oral medication called deucrictibant to prevent and treat swelling attacks in people with hereditary angioedema. It may help reduce the number and severity of attacks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with a type of swelling called bradykinin-mediated angioedema (swelling that doesn't improve with allergy medicines).
- You have had at least 2 swelling attacks in the last 2 months.
- You are able to use your usual rescue medication for attacks.
- You are not taking certain blood pressure medicines (ACE inhibitors) or estrogen-containing medications (like birth control pills).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a long-term daily pill to prevent swelling attacks in people with hereditary angioedema (HAE). The pill, called deucrictibant, is designed to block a protein involved in causing attacks. It's for adolescents and adults who want to reduce how often swelling episodes occur.
This study is an extension trial of an oral medicine (PHA-022121) for treating acute attacks in people with hereditary angioedema (HAE), especially HAE type III (HAE-nC1INH). It checks whether continuing this oral treatment can safely help manage attacks after you’ve taken it before.
This study checks if a blood test measuring C1-inhibitor function can help diagnose hereditary angioedema (HAE), a rare condition that causes painful swelling episodes. If you or a close family member have had swelling without rash or itching that lasts 1-5 days and doesn't get better with allergy meds, this trial may be for you.
This trial tests if lanadelumab can prevent swelling attacks in people with acquired angioedema (AAE). Acquired angioedema is a rare condition that causes sudden swelling in the skin and other body parts. This medicine is given as a long-term shot to lower the number of attacks you have.
This study tests a new medicine, donidalorsen, to prevent swelling attacks in children ages 2 to 11 with hereditary angioedema (HAE). If your child has HAE type 1 or 2, this trial may help find a treatment option.
This study is for people who already finished a previous trial of the drug ADX-324 for hereditary angioedema. It tests the long-term safety and effectiveness of continuing the medication.
Hear when a new Hereditary Angioedema (HAE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.